Press Releases

NeuBase Therapeutics Announces Proposed Public Offering of Common Stock

Apr 21, 2021 4:01pm EDT

NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases

Apr 08, 2021 8:00am EDT

NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference

Mar 16, 2021 8:00am EDT

NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021

Mar 09, 2021 7:00am EST

NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021

Feb 11, 2021 4:01pm EST

NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics

Jan 28, 2021 8:00am EST

NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Jan 11, 2021 6:00am EST

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020

Dec 23, 2020 4:05pm EST

NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL™-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1

Dec 16, 2020 6:30am EST

NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer

Dec 02, 2020 8:00am EST

1
2
3
4
5
6